References
- Santana V., Rose R. N. lmmunodysregulation and malignant lymphoproliferative disorders. Recent Adoances in Clinical Immunology. Churchill Livingstone, New York 1983; 51–67
- Lukes R. J., Collins R. D. Immunologic characterization of human malignant lymphoma. Cancer 1974; 34: 1488–1503
- Lichtenstein A., Levine A. M., Lukes R. J., Cramer A., Taylor C., Lincoln T. L., Feinstein D. lmmunoblastic sarcoma: A clinical description. Cancer 1949; 43: 343–352
- Levine A. M., Taylor C. R., Shneider D. R., et al. Immunoblastic sarcoma of T-cells vs 9–cell origin: 1. Clinical Features. Blood 1981; 58: 52–61
- Combes B., Stastny P., Shorey J., et al. Glomerulonephritis with deposition of australia antigen-antibody complexes in glomerular basement membrane. Lancet 1971; 11: 234–237
- Dobbs D. J., Morel-Maroger Striker I., Mignon F., Striker G. Glomerular lesions as lymphomas and leukemias. Am. J. Med. 1986; 80: 63–70
- Lam K. C., Lai C. L., Trepo C., Wu P. C. Deleterious effect of prednisolone in HBsAg positive chronic hepatitis. N. Eng. J. Med. 1981; 304: 380–386
- European Association for the Study of the Liver. A multicenter randomized clinical trial of low-dose steroid treatment in chronic active HBsAg positive liver disease. Gastroenterology 1984; 86: 1317
- Scullard G. H., Smith C. I., Merigan T. C., Robinson W. S., Gregory P. B. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gasrroenterology 1981; 81: 987–991
- Mueller R., Vido, Schmidt F. W. The effect of rapid withdrawal of immunosuppressive therapy in patients with chronic active hepatitis. International Symposium. Franklin Institute Press, Philadelphia 1981; 647
- Weller I. V., Bassendine M. F., Murray A. K., Craxi A., Thomas H., Sherlock S. Effects of pred-nisolone/azathioprine in chronic hepatitis B viral infection. Gut 1982; 23: 65C–655
- Hoofnagle J. H. Chronic hepatitis: The role of corticosteroids. Viral Hepatitis, W. Szmunes, H. J. Alter, J. E. Maynard. Franklin Institute Press, Philadelphia 1982; 573–582
- Hoofnagle J. H., Dusheiko G. M., Schafer D. F., et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann. Int. Med. 1982; 96: 447–449
- Oefinger E. P., Bronson L. D., Dreesman R. G. Induction of hepatitis B surface antigen in human hepatomaderived cell line. J. Gen. Virol. 1981; 53: 105–113
- Tur Kaspa R., Burk R. D., Shaul Y., Shafritz D. A. Hepatitis B virus DNA contains a glucocorticoid responsive element. Proc. Natl. Acad. Sci., USA 1986; 83: 1627–1631
- Shafritz D. A., Shouval D., Sherman H. I., Hadziyannis S. J., Kew M. D. Integration of hepatitis B virus DNA in chronic liver disease and hepatocellular carcinoma. J. Engl. J. Med. 1981; 305: 1067–1073
- Romet-Lemonne J. L., McLane E. M. Hepatitis B virus infection in cultured human lymphoblastoid cells. Science 1984; 221: 667–669